With new CEO, Passage Bio gives early look at first six patients in GM1 gangliosidosis gene therapy trial

Lei Lei Wu

News Reporter

Passage Bio has passed through a rough stretch of layoffs, exec departures, and pipeline cuts this past year.

And with a new CEO in William Chou, who joined in October from Aruvant after parent company Roivant scrapped its sickle cell program, Passage Bio is looking to recalibrate. It’s starting with some very early results from its gene therapy for GM1 gangliosidosis, a rare disease in which people, often infants or children, don’t make any or enough of an enzyme called beta-galactosidase-1 that helps break down large sugars.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

With new CEO, Passage Bio gives early look at first six patients in GM1 gangliosidosis gene therapy trial

Lei Lei Wu

News Reporter

Unlock this article instantly by becoming a free subscriber.

House to mark up bill targeting Chinese biotech and genomics companies

FDA asks for more data on Dupixent in COPD in move that could delay a decision

AbbVie puts $161M into new R&D site in Germany, will add 300 jobs

Epigenetic editing startup Chroma lays off staff, focusing on reaching the clinic

WuXi wants to regain client confidence amid claims of IP transfer to Chinese authorities

A New Precision Approach for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

With new CEO, Pas­sage Bio gives ear­ly look at first six pa­tients in GM1 gan­gliosi­do­sis gene ther­a­py tri­al

Lei Lei Wu

News Reporter

Unlock this article instantly by becoming a free subscriber.

House to mark up bill tar­get­ing Chi­nese biotech and ge­nomics com­pa­nies

FDA asks for more da­ta on Dupix­ent in COPD in move that could de­lay a de­ci­sion

Ab­b­Vie puts $161M in­to new R&D site in Ger­many, will add 300 jobs

Epi­ge­net­ic edit­ing start­up Chro­ma lays off staff, fo­cus­ing on reach­ing the clin­ic

WuXi wants to re­gain client con­fi­dence amid claims of IP trans­fer to Chi­nese au­thor­i­ties

A New Pre­ci­sion Ap­proach for Non-Small Cell Lung Can­cer with EGFR Ex­on 20 In­ser­tion Mu­ta­tions

With new CEO, Passage Bio gives early look at first six patients in GM1 gangliosidosis gene therapy trial

House to mark up bill targeting Chinese biotech and genomics companies

FDA asks for more data on Dupixent in COPD in move that could delay a decision

AbbVie puts $161M into new R&D site in Germany, will add 300 jobs

Epigenetic editing startup Chroma lays off staff, focusing on reaching the clinic

WuXi wants to regain client confidence amid claims of IP transfer to Chinese authorities

A New Precision Approach for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations